136 related articles for article (PubMed ID: 34275333)
1. Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes.
Marden JR; Santos C; Pfister B; Able R; Lane H; Somma M; Zhao J; Signorovitch J; Parsons J; Apkon S
J Comp Eff Res; 2021 Oct; 10(14):1065-1078. PubMed ID: 34275333
[No Abstract] [Full Text] [Related]
2. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy.
Shieh PB; Elfring G; Trifillis P; Santos C; Peltz SW; Parsons JA; Apkon S; Darras BT; Campbell C; McDonald CM; ; ; ;
J Comp Eff Res; 2021 Dec; 10(18):1337-1347. PubMed ID: 34693725
[No Abstract] [Full Text] [Related]
3. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
4. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
5. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
[No Abstract] [Full Text] [Related]
6. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study.
Wong BL; Cook T; Miller H
J Comp Eff Res; 2022 Aug; 11(11):779-786. PubMed ID: 35713895
[TBL] [Abstract][Full Text] [Related]
7. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
[No Abstract] [Full Text] [Related]
10. Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids.
Abutaleb ARA; McNally EM; Khan SS; Anderson AS; Carr JC; Wilcox JE
JAMA Cardiol; 2018 Oct; 3(10):1006-1010. PubMed ID: 30167630
[TBL] [Abstract][Full Text] [Related]
11. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
14. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.
McDonald CM; Mayer OH; Hor KN; Miller D; Goemans N; Henricson EK; Marden JR; Freimark J; Lane H; Zhang A; Frean M; Trifillis P; Koladicz K; Signorovitch J;
J Neuromuscul Dis; 2023; 10(1):67-79. PubMed ID: 36565131
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
[TBL] [Abstract][Full Text] [Related]
17. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Singh A; Schaeffer EK; Reilly CW
J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
19. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
Rice ML; Wong B; Horn PS; Yang MB
J AAPOS; 2018 Jun; 22(3):192-196. PubMed ID: 29733899
[TBL] [Abstract][Full Text] [Related]
20. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
